Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

PolyNovo

Request full access

Synthetic biodegradable matrix for complex wound reconstruction.

Melbourne, AustraliaFounded 1998Biotech & Life Sciences

About PolyNovo

PolyNovo Limited is a medical technology company that designs, develops, and manufactures dermal regeneration solutions. The company was established in 2004 as a spin-off from Australia's Commonwealth Scientific and Industrial Research Organisation (CSIRO) by researchers Thilak Gunatillake, Raju Adhikari, and Roshan Mayadunne, who developed a novel biodegradable polyurethane. The technology's potential for wound care was explored in collaboration with burns surgeon Professor John Greenwood, inspired by the need for better treatments following events like the 2002 Bali bombings. After a period of restructuring, the company relisted in 2014 as PolyNovo and has since focused purely on commercializing its medical device platform. The company's core business revolves around its proprietary NovoSorb® technology, a patented family of biocompatible and bioresorbable polymers. This technology is the foundation for its flagship product, NovoSorb® BTM (Biodegradable Temporizing Matrix). NovoSorb BTM is a fully synthetic, bilayer medical device designed for the treatment of complex wounds, such as severe burns and trauma, where the dermal layer of skin has been lost. The device consists of a 2mm biodegradable open-cell foam that acts as a scaffold for the body to regenerate a new dermal layer, and a temporary sealing membrane that protects the wound and prevents moisture loss. Once the new tissue is vascularized, the seal is removed, ready for definitive closure. A key differentiator from biologic-based competitors is that its synthetic nature does not provide a food source for bacteria, making it robust in the presence of infection. PolyNovo's business model is focused on the sale of its NovoSorb products directly to hospitals and surgeons. The company has established a significant direct sales force, particularly in the United States, which is its largest market and accounts for the majority of its revenue. The firm also operates in Australia, New Zealand, the UK, and Ireland, and uses distributors to access markets in Europe and Canada. Revenue is primarily generated from sales of NovoSorb BTM and its newer product, NovoSorb MTX, a single-layer version for wounds that do not require a sealing membrane. The company is pursuing growth by expanding the indications for its existing products, deepening penetration in current markets, and entering new geographic territories like China and Japan. It is also developing new products based on the NovoSorb platform for applications in hernia repair and breast reconstruction.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 1999
Outcome tier
Unicorn$1–10B valuation tierColt$25–100M revenue

PolyNovo in the Melbourne ecosystem

Live from Dealroom

The PolyNovo office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • HHS Administration for Strategic Preparedness and Response
  • Industry R&D Infrastructure Fund

Series B and later1 investor entered at this stage

  • Monash University
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
9 countries with
team presence
🇺🇸 United States45.2%
🇦🇺 Australia40.9%
🇮🇳 India7.4%
🇬🇧 United Kingdom3%
🇳🇿 New Zealand1.3%
Top 5 of 9 shown

Patents

Estimated portfolio value
$15M

7 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about PolyNovo on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PolyNovo on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.